NEW YORK, NY / ACCESSWIRE / March 23, 2017 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against SITO Mobile, Ltd. (“SITO” or the “Company”) (NASDAQ: SITO) and certain of its officers, and is on behalf of purchasers of SITO securities between February 9, 2016, and January 2, 2017, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/sito.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) SITO’s development of bookings would not drive the Company’s fourth fiscal quarter 2016 media placement revenues and revenue growth to the level represented during the Class Period; (2) SITO was aware that the election would impact its fourth fiscal quarter 2016 revenue, (3) clients’ campaign spending and media placement revenues in the fourth quarter 2016 was highly dependent on the elections; (4) SITO’s growth in media placement revenues would not occur in the fourth fiscal quarter 2016; (5) consequently, SITO’s statements about its business, operations, and prospects were false and misleading and/or lacked a reasonable basis.

On January 3, 2017, SITO released discouraging quarterly revenue results for its preliminary media placement for the quarter ending December 31, 2016. SITO said its results were “negatively affected this year by restrained advertising spending during a period of heightened and elongated media focus on this year’s U.S. election.” Jerry Hug, SITO’s CEO, was quoted, “We clearly underestimated the effects of this year’s election on our clients’ campaign spending.” Despite a positive conference call in the third quarter where Hug told an analyst that there would not be a significant drop from the election, the discouraging results came shortly after the SITO’s repeated hype and positive forecast. Following this news, SITO stock dropped 32% on January 3, 2017.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: http://www.bgandg.com/sito, or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in SITO, you have until April 18, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 455852

NEW YORK, NY / ACCESSWIRE / March 23, 2017 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against FXCM Inc. (“FXCM” or the “Company”) (NASDAQ: FXCM) and certain of its officers, on behalf of a class who purchased FXCM securities between March 15, 2012 and February 6, 2017, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/fxcm.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) between September 4, 2009 through at least 2014, FXCM’s U.S. subsidiary were engaged in false and misleading solicitations of its retail foreign exchange customers by hiding its relationship with its most important market maker and by misrepresenting that its “No Dealing Desk” platform had no conflicts of interest with its customers; (2) FXCM’s U.S. subsidiary made false statements to the National Futures Association about its relationship with the market maker; and (3) consequently, Defendants’ statements regarding FXCM’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

On February 6, 2017, the Commodities Futures Trading Commission (“CFTC”) found that FXCM was engaged in false and misleading solicitations of its retail foreign exchange customers by hiding its relationship with FXCM’s most important market maker and the fact that the Company’s “No Dealing Desk” platform had conflicts of interest with FXCM’s customers. Due to the above, CFTC barred FXCM from operating in the United States. Following this news, FXCM stock dropped $3.40 per share, or 50%, to close at $3.45 on February 7, 2017.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: www.bgandg.com/fxcm, or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in FXCM, you have until April 10, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 454666

NEW YORK, NY / ACCESSWIRE / March 23, 2017 / Two stocks that investors gained confidence in on Wednesday are both getting attention from stockholders on recent news announcements. Both the companies may become a topic of discussion involving a potential buyout as a result of the positive financial and investment news. Investors are awaiting future updates that will occur over the next several weeks to determine whether today’s news will spurn a rise in the price of the stocks.

RDI Initiates Coverage:

Idera Pharmaceuticals
Inc. https://ub.rdinvesting.com/news/?ticker=IDRA

XOMA Corporation https://ub.rdinvesting.com/news/?ticker=XOMA

Idera Pharmaceuticals stock rose by $0.40 a share on Wednesday to close at $2.49, up more than 19%. Several reasons were attributed to the stock’s rise. First, JMP Securities of the JMP Group issued an “outperform” for the stock today as its initial rating. Its assigned target price for the stock is $8 per share. The second reason is the investor optimism for the company as it will present two of its hot candidates, at the American Association for Cancer Research meeting on April 1st – 5th. Two presentations for its lead candidate cancer drug, IMO-2125 are scheduled for the early morning of April 5th. Consensus of analysts has called for “buy” rating on the stock with average target price of $5.00, according to The Wall Street Journal. The Company has reported a profit of $0.8 million or $0.01 a share on revenue of $15.3 million for the fourth quarter of 2016 as compared to loss of $12 million or $0.1 a share on a revenue of $190,000 reported in the same quarter in the prior year. Jump in the revenue in the last quarter was primarily due to the Vivelix agreement, signed in November 2016. The company has seen its share price gain more than 75 percent over the last 60 days, and the presentation may further boost investor’s confidence in the IMO-2125 protocol.

Access RDI’s Idera Pharmaceuticals Research Report at: https://ub.rdinvesting.com/news/?ticker=IDRA

At Wednesday’s close, XOMA Corporation found its stock scoot up $0.70 per share on Wednesday, to close at $6.045. The 13 percent increase was fueled by news that the company had fully prepaid its capital debt to Hercules Technology Growth, and it will reduce its general operating expenses while strengthening the overall balance sheet. This step introduces the company’s new business strategy, as the company has now decreased its debt by 39 percent or by $16.7 million in past three months. During the month of February, XOMA has funded itself with $25 million worth of registered offering of common stocks and convertible stocks to BVF Partners and also appointed Mr. Matthew Perry, President of BVF Partners to XOMA’s board of directors. Two weeks ago, some XOMA investors were surprised at the uptick in the stock price, with no apparent reason connected to it. After hours trading saw a slight retreat in the price of the stock.

Access RDI’s XOMA Corporation Research Report at: https://ub.rdinvesting.com/news/?ticker=XOMA

Our Actionable Research on Idera Pharmaceuticals Inc. (NASDAQ: IDRA) and XOMA Corporation (NASDAQ: XOMA) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458004

NEW YORK, NY / ACCESSWIRE / March 23, 2017 / Appointment of Steve Gottlieb in early March by President Trump to lead the FDA is generally seen as positive for the Biotech sector. A general relaxation of regulations that are likely to speed up the FDA approval process is now expected by companies and investors. Earlier in the year in its January 27th edition, Forbes stated that “our medical establishment lacks the leadership it needs to shift its efforts from disease cures to disease prevention.” Biotech companies that are in that subcategory, can possibly expect significant investor interest over the next 4 years.

RDI Initiates
Coverage:

Moleculin Biotech
Inc.
https://ub.rdinvesting.com/news/?ticker=MBRX

Innocoll Holdings PLC
https://ub.rdinvesting.com/news/?ticker=INNL

Moleculin Biotech investors saw its stock go up almost 25 percent on Wednesday, to close at $1.33 per share. The gain of $0.26 per share comes after its lead candidate drug, Annamycin, an anthracycline used in the treatment of Acute Myeloid Leukemia has been awarded status as an orphan drug by the FDA. An orphan drug designation is given to pharmaceutical companies that develop drugs for rare diseases, in many cases resulting in financial incentives to further incentivize development of the product. Moleculin began trading on NASDAQ on June 2nd, last year, at a price of $8.00 a share as compared to IPO price of $6 per share and since early January this year it is trading in the range near $2 to $1. Moleculin Biotech is a pre-clinical pharmaceutical company and it is working in collaboration with MD Anderson Cancer Center in Houston. The stock continued to gain ground in after-hours trading, adding another $0.02 to its share price.

Access RDI’s Moleculin Biotech Research Report at:
https://ub.rdinvesting.com/news/?ticker=MBRX

Innocoll Holdings stock closed Wednesday’s trading session at $1.19, up $0.14 on the day. The company is a pharmaceutical and medical device company, specializing in the manufacture and sale of collagen-based products and medical devices. It sales territory includes Europe, the Middle East, Asia, and the United States for its different products. Among its product offerings are CollaGUARD, Septocoll, and RegenePro. Its lead candidate XaraColl, has achieved positive pivotal results in Phase 3 clinical trials, however, U.S. FDA has rejected it filing for XaraColl, and the company received refusal to file a letter on December 29, last year, requiring additional information and explanation. Subsequently lawsuits have been filed by shareholders earlier this year, regarding Innocoll’s submission of XaraColl and for misleading statements about company’s business operations and prospects, however its stock price hasn’t been affected by those lawsuits. The company has seen improved sales in year 2016 over year 2015 and as of December 31st, 2016 it reported a cash balance of $15.6 million as compared to cash balance of $30.4 million reported on September 30th, 2016.

Access RDI’s Innocoll Holdings Research Report at:
https://ub.rdinvesting.com/news/?ticker=INNL

Our Actionable Research on Moleculin Biotech Inc. (NASDAQ: MBRX) and Innocoll Holdings PLC (NASDAQ: INNL) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458002

NEW YORK, NY / ACCESSWIRE / March 23, 2017 / Vishay Precision Group, Inc. (NYSE: VPG), a leading producer of precision sensors and systems, announced today that it will be presenting at the Sidoti & Company Spring 2017 Convention on March 29th at 4:10 p.m. EDT. Bill Clancy, Executive Vice President and Chief Financial Officer, will be presenting, as well as meeting with investors.

http://wsw.com/webcast/sidotico3/vpg

Sidoti & Company is the preeminent, institutional-quality equity research provider on Wall Street covering small- and micro-cap equities. We are building interest and visibility into the most overlooked, undervalued segment of the equity market. Sidoti & Company aims to unite small- and micro-cap companies together with quality investors.

News Compliments of ACCESSWIRE.

About VPG

Vishay Precision Group (VPG) is an internationally recognized designer, manufacturer and marketer of: components based on its resistive foil technology, sensors, and sensor-based systems specializing in the growing markets of stress, force, weight, pressure, and current measurements. VPG is a market leader of foil technology products, providing ongoing technology innovations in precision foil resistors and foil strain gages, which are the foundation of the company’s force sensors products and its weighing and control systems. The product portfolio consists of a variety of well-established brand names recognized for precision and quality in the marketplace. To learn more, visit VPG at www.vpgsensors.com.

About Sidoti & Company

Sidoti & Company, LLC is Wall Street’s preeminent provider of equity research generally focused on companies with market capitalizations of under $3 billion. We cover over 250 companies across a range of industries. The companies covered by our traditional research typically have a history of profitability, maintain strong balance sheets, and tend to have limited, if any, coverage by other Wall Street firms.

Our approach affords institutional investor clients a combination of high-quality research, a small- and micro-cap company focused on a nationwide sales effort, broad access to corporate management teams, and extensive trading support. We serve nearly 500 institutional clients in the U.S., Canada, and the U.K., including many leading managers of portfolios with $200 million to $2 billion of assets. We believe that these asset managers are generally underserved by other larger brokerage firms that typically target larger managers.

Sidoti also hosts a fee-based biannual Emerging Growth Convention in New York, and is a provider of company sponsored research.

We are a broker-dealer registered with the SEC and a FINRA member firm. We provide a broad range of securities-related services. In addition to our high-quality research, our sales and trading services are distinguished by prompt execution, a competitive commission structure and access to smart order routing that utilizes all available sources of liquidity. From time to time, we are invited to participate as an underwriter, dealer, placement agent, or initial purchaser in securities offerings for issuers for which we provide research coverage. Given our knowledge of the companies we cover, we believe that we are able to contribute to these capital-raising transactions. We also assist our issuers with stock repurchase programs, block trades and organized (Rule 10b5-1) trading plans.

For those interested in attending, please contact Caitlin Adams at conference@sidoti.com or visit http://www.sidoti.com/events/ for more information.

Contact:

Bill Clancy, Chief Financial Officer
484-321-5306
Investors@vpgsensors.com

SOURCE: Vishay Precision Group, Inc.

ReleaseID: 458022

NEW YORK, NY / ACCESSWIRE / March 23, 2017 / The news for both Biocept and OvaScience is that investors will have to await further news to see if today’s gains hold. Biocept investors are awaiting news on the presentation the company made at a conference today, while OvaScience investors look for clues to the reasons for today’s bump. An increased trading volume caused investors to take a second look at the stocks for their upside potential.

RDI Initiates
Coverage:

Biocept Inc. https://ub.rdinvesting.com/news/?ticker=BIOC

OvaScience Inc. https://ub.rdinvesting.com/news/?ticker=OVAS

Stock analysts were impressed by Biocept’s stock movement on Wednesday, the company’s stock was up $0.16 to close at $2.34. One noticeable thing was the trading volume that reached more than 2.8 million shares on the day, the stock has trended upward since early November of last year. The company is involved in the development of early cancer diagnostic technologies. It made a presentation on Wednesday, March 22nd at the 27th Annual Oppenheimer Healthcare Conference, and as a result investors are showing their optimism and are awaiting a report from the company on the results of the conference presentation. After hours trading has the company’s stock down slightly.

Access RDI’s Biocept Research Report at: https://ub.rdinvesting.com/news/?ticker=BIOC

Some investors took a long position on OvaScience on Wednesday as the company is sparking long term interest on the continued development of one of its fertility treatment options for women, available worldwide. OvaPrime is intended to avoid hormone treatment therapy injections by producing mature fertilizable eggs from the woman’s own EggPC cells, it is currently enrolling for company sponsored trials that will complete in the first half of 2017. With $114.4 million in cash, cash equivalents and short term investments as on December 31, 2016, the company finds itself sufficiently funded to progress the clinical development of OvaPrime, at least until the end of 2018. The stock closed at $1.72 a share, up $0.12 on the day. While the consensus of analysts called for a “hold” on the stock, it appears the stock will approach $2 per share. On Wednesday, the stock traded fairly evenly, but both the 5 day and the 30 day trends show a consistent rise in price. After hours trading continued the rise, edging up another $0.02.

Access RDI’s OvaScience Research Report at: https://ub.rdinvesting.com/news/?ticker=OVAS

Our Actionable Research on Biocept Inc. (NASDAQ: BIOC) and OvaScience Inc. (NASDAQ: OVAS) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458006

NEW YORK, NY / ACCESSWIRE / March 23, 2017 / Both GoPro and Snap are popular technology companies that have had early successes. As time has moved on, they have run into serious long term competition from established competitors such as LG and Instagram, respectively. This is where the problem is for investors, as the focus for both companies needs to be on their long term prospects, as neither is currently positioned to make significant short term headway.

RDI Initiates
Coverage:

GoPro Inc. https://ub.rdinvesting.com/news/?ticker=GPRO

Snap Inc. https://ub.rdinvesting.com/news/?ticker=SNAP

GoPro’s shares fell $0.07 in Wednesday’s trading, to close at $8.33. The company recently announced a total of 450 layoffs and a reduction in operating expenses by more than $200 million to bring the company to profitability. These decisions were made after the company posted more than disappointing revenues for the last two quarters of 2016. Investment analysts are not impressed about the recent enthusiasm in the stock, maintaining that the issue is sales, not cost cutting.

Access RDI’s GoPro Research Report at: https://ub.rdinvesting.com/news/?ticker=GPRO

Recently, Snap has received two “buy” ratings in the last two days – one from Drexel Hamilton, the other from Monness Crespi Hardt. The stock closed on Wednesday up $1.44 a share to close at $21.82. The rise can be partly attributed to the buy signals but many investors are still questioning whether the buy signals are justified. There have been a number of popular high tech IPOs, but the unfortunate history is that the vast majority of them fail to make investor’s money over the long term. Examples include Zynga, Etsy, and GoPro, all who have registered double digit percentage losses. Facebook and Alibaba are the only two stocks that have justified investor’s optimism over the long haul. So why the “buy” ratings? Though Snapchat is currently not the choice of marketers, Drexel’s Brian White made its case for the recommendation by stating that “the company simply has a more popular product among millennials, which is clearly making the case for the prime 18-35 market demographic.” Drexel also supported the youthful key management positions of Chief Executive Spiegel and Chief Technology Officer Murphy by comparing them to Apple’s Steve Jobs and what he did with Apple at such a young age. Brian White predicted that Snapchat’s revenue would increase by 118% in 2017 and by 100% in 2018. Before Drexel’s “buy” ratings on today, Snap had a consensus rating of “underweight” with an average target price of $18.50 according to The Wall Street Journal.

Access RDI’s Snap Research Report at: https://ub.rdinvesting.com/news/?ticker=SNAP

Our Actionable Research on GoPro Inc. (NASDAQ: GPRO) and Snap Inc. (NYSE: SNAP) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458013

NEW YORK, NY / ACCESSWIRE / March 23, 2017 / Both companies have had their own troubles recently, with Nike’s reported fiscal 3rd quarter earnings not impressing investors and Sears revealing that its February restructuring plans have not gone as planned. Earlier in the year, The Wall Street Journal reported that mall owners were seeking to revamp their properties but were often tied into long term agreements with major retailers such as Sears and Kmart. This followed holiday violence over the Christmas holiday at several mall locations around the country. Sears, Kmart, and Nike all have a strong presence in major malls throughout the country.

RDI Initiates
Coverage:

Sears Holdings Corp. https://ub.rdinvesting.com/news/?ticker=SHLD

Nike Inc. https://ub.rdinvesting.com/news/?ticker=NKE

Sears Holdings dropped more than 12% in Wednesday’s trading, falling $1.12 a share to close at $7.98. The downward trend is likely to continue based on the company’s record of 7 years of continuous losses, and now there are reports that it may not be able to have sufficient cash to keep operating unless financial stability can be attained. Sears Holdings, who owns both the Sears and Kmart brands, said in its annual report that, “substantial doubt exists related to the company’s ability to continue as a going concern.” After hours trading saw the company’s shares continue to fall. Eddie Lampert, its CEO, Chairman and largest investors with a nearly 48 percent stake, in an investor’s mind, is perhaps the only person standing between the department store chain and bankruptcy. Back in February of this year, Sears Holdings announced it would close 150 more stores and lay off additional employees that will result in a $1 billion restructuring process.

Access RDI’s Sears Holdings Research Report at: https://ub.rdinvesting.com/news/?ticker=SHLD

Nike’s stock fell $4.09 a share on Wednesday to close at $53.92. The drop in price was surprising due to two contrasting factors. While the company reported earnings for its 3rd quarter to be higher than expected, up to $0.68 per share up from $0.55 per share reported in the same quarter during the prior year, the increase was less attributed to a rise in revenues, but more to a reduction in expenses. Annual sales totaled $8.43 billion, which is a 5 percent increase year-over-year from the $8.03 billion reported last year, but the results fell below an expected $8.47 billion in sales. Expected global orders over the next 6 months are projected to be down by 4 percent and analysts are speculating that Nike is having trouble dealing with a more competitive environment and the changing retail landscape.

Access RDI’s Nike Research Report at: https://ub.rdinvesting.com/news/?ticker=NKE

Our Actionable Research on Sears Holdings Corp. (NASDAQ: SHLD) and Nike Inc. (NYSE: NKE) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458012

NEW YORK, NY / ACCESSWIRE / March 23, 2017 / Bulldog Reporter is excited to announce the winners of the 2017 Bulldog Media Relations Awards program. Almost 200 submissions were entered this year with award winners outlined below.

As with all Bulldog Awards, the Media Relations program is judged by award-winning journalists, including a Pulitzer Prize winner. This year’s judges come from several different media outlets, including The Washington Post, USA Today, Forbes, and The Oregonian.

This year, 62 firms have won honors in 30 categories. The Grand Prize Winner for the 2017 Best Media Relations Campaign of the Year goes to Sparkpr, who won one Silver and two Gold awards, including Best New Product Launch – Business, Best General Business Campaign, and Best Technology Campaign – Business for their campaign, Boom Supersonic: Breaking Through The Sound Barrier.

Bulldog Reporter will be revamping and refreshing the Bulldog Awards this year to better reflect the modern PR industry. Stay tuned to the website (https://www.bulldogreporter.com/awards/), as further details will be posted within the next month.

The full list of 2017 Bulldog Media Relations Awards winners are below.

GRAND PRIZE WINNER
2017 Best Media Relations Campaign of the Year
Sparkpr for Boom Supersonic: Breaking Through The Sound Barrier

Best Arts & Entertainment Campaign

GOLD AWARD: Adam Ritchie Brand Direction for T.R.I.P. Album + Beer Launch
SILVER AWARD: Collab for Launch of Collab – Helping Creators Earn a Living Doing What They Love
BRONZE AWARD: Miller PR for Meet The New Housewife, Dorit Kemsley

Best Campaign Under $10,000

GOLD AWARD: Uproar PR for GOAT Story Launch Campaign
SILVER AWARD: Finn Partners for Carvel Free Cone Day – “Kicking Off Ice Cream Season!”
BRONZE AWARD: Bullfrog + Baum for LEAP by B+B

Best Campaign Under $25,000

GOLD AWARD: M&C Saatchi PR for IT’SUGAR ONE SCARY ELECTION
GOLD AWARD: Scott Circle for Scott Circle & DCPLF – UNCENSORED: Banned Books Week
SILVER AWARD: M&C Saatchi PR for A Grand Slam Start-Up Launch for GameHedge
BRONZE AWARD: The Hoffman Agency for Predictive Planning and Industry Smarts Earn Sharper Shape Top-tier Buzz

Best Campaign Under $50,000

GOLD AWARD: M&C Saatchi PR for A SNACKING REVOLUTION: LAUNCHING HIPPEAS IN THE U.S.

Best Campaign Under $100,000

SILVER AWARD: Ogilvy Public Relations for Low Battery Anxiety
BRONZE AWARD: Ruder Finn for Polaroid Swing
BRONZE AWARD: Belle Communications with Lextant for Strategic Thought Leadership Campaign Delivers $1.5 Million+ in New Revenue

Best Company Positioning/Branding

GOLD AWARD: Current Marketing for Drink Amazing
SILVER AWARD: IBM for Defining Cognitive Creativity with IBM Watson
BRONZE AWARD: French/West/Vaughan for Operation POTUS

Best Crisis Communications

SILVER AWARD: JCP&L for JCP&L Preps Customers for Winter Storm Jonas
BRONZE AWARD: PAN Communications for The Day the Internet Broke- Dyn’s DDos Attack Crisis

Best Education/Public Service Campaign

SILVER AWARD: Edelman Italy for Sport at the Service of Humanity
BRONZE AWARD: FirstEnergy for Power Systems Institute Re-Launch Campaign – FirstEnergy Corp.

Best Food & Beverages Campaign

GOLD AWARD: M&C Saatchi PR for A SNACKING REVOLUTION: LAUNCHING HIPPEAS IN THE U.S.
SILVER AWARD: Dairy Queen, Crossroads and Barkley for DQ Singles Blizzard
BRONZE AWARD: RF|Binder and Dunkin’ Donuts for Dunkin’ Donuts Crafts Coffee and Beverage Coverage in 2016

Best General Business Campaign

GOLD AWARD: Sparkpr for Boom Supersonic: Breaking Through The Sound Barrier
SILVER AWARD: ICR for ICR + USCR: A Breakthrough in Reputation & Growth
BRONZE AWARD: SHIFT Communications for Accounting for Success for AccountantsWorld

Best General Consumer Campaign

GOLD AWARD: 3rd Coast PR for Lakeshore Learning: Teaching Parents the Value of Educational Toys at Home
SILVER AWARD: Neff Associates for goPuff- Becoming the “WaWa on Wheels”
BRONZE AWARD: Current for Brita – Drink Amazing

Best Green Campaign

GOLD AWARD: Duffy & Shanley for Deepwater Wind: America’s First Offshore Wind Farm Powers Up

Best Health, Medicine & Fitness Campaign

GOLD AWARD: Abbott and GCI Health for The Launch of Absorb: A Revolutionary, Game-Changing, First-of-Its-Kind Fully Dissolving Heart Stent
SILVER AWARD: 919 Marketing for Visiting Angels: Mother’s Day Makeover
BRONZE AWARD: Cigna for For The First Time Ever, TV Doctors Save Real Lives!

Best Investment, Banking & Financial Services Campaign

SILVER AWARD: State Street Corporation for Investing Capital to Create Change: State Street’s SHE Gender Diversity ETF Campaign
BRONZE AWARD: RF|Binder Partners for The New Chubb: Unifying the Reputations of Two Revered Insurance Brands

Best Issue/Cause Advocacy Campaign

GOLD AWARD: Havas PR North America for The 4A’s: An Industry Under Fire Comes Out Swinging
SILVER AWARD: Cigna for Away From Blame: Cigna’s Initiative To Fight The U.S. Opioid Epidemic
BRONZE AWARD: Kivvit for A Campaign for Justice on Nazi Stolen Art on Moral Grounds (and Dame Helen Mirren)
BRONZE AWARD: Henry Schein for Henry Schein ‘Helping Health Happen’ for 5.5 Million Children in Need of Oral Care

Best New Product Launch – Business

GOLD AWARD: Havas PR North America for The Barnacle: Giving The Boot the Boot
SILVER AWARD: Sparkpr for Boom Supersonic: Breaking Through The Sound Barrier
BRONZE AWARD: PAN Communications for Sisense Disrupts BI Market, Brings AI and IoT to the Enterprise

Best New Product Launch – Consumer

GOLD AWARD: UPRAISE Marketing + Public Relations for “The Most Frustrating Chore” Goes Viral – FoldiMate
SILVER AWARD: Havas PR North America for Making Green Giant Big Again
BRONZE AWARD: O’Reilly DePalma for Howie Mandel Leads the ActiClean Patrol to Launch a New Self-Cleaning Toilet

Best Not-for-Profit/Association/Government Campaign

GOLD AWARD: Vanguard Communications and the American Psychological Association for Stress in America- Election Stress
SILVER AWARD: Hollywood Public Relations for The Mayflower II’s Long Journey Home
BRONZE AWARD: Health Resources and Services Administration for National Health Service Corps – Corps Community Month 2016

Best Response to Breaking News

GOLD AWARD: Merritt Group for Positioning an Unknown Cybersecurity Vendor at the Forefront of a Major Presidential Campaign Crisis
SILVER AWARD: MorphoTrust USA & RH Strategic Communications for MorphoTrust USA Promotes TSA Pre-Check
BRONZE AWARD: Landis Communications Inc. for “LCI Reacts to Oakland’s Ghost Ship Fire, Connects Community to Chapel of the Chimes For Support”

Best Special Event/Stunt

GOLD AWARD: French/West/Vaughan for Wrangler Honors Greensboro’s Textile History
SILVER AWARD: Strauss Media Strategies for Democratic National Convention 2016
SILVER AWARD: EvansHardy+Young for The Big Idaho Potato Meets the Big Apple
BRONZE AWARD: Laughlin Constable for Wisconsin Department of Tourism’s Wisconsin Weekend in Chicago
BRONZE AWARD: Rogers & Cowan for AARP Movies For Grown-ups 2016

Best Technology Campaign – Business

GOLD AWARD: Sparkpr for Boom Supersonic: Breaking Through The Sound Barrier
SILVER AWARD: Arketi Group for NCR Silver – Focused Media Relations Builds a Technology Thought Leader
BRONZE AWARD: Havas PR North America for The Barnacle: Giving The Boot the Boot
BRONZE AWARD: Diffusion for Global Wireless Solutions Goes for Gold for Network Connectivity in Rio, with Forbes

Best Technology Campaign – Consumer

GOLD AWARD: Ogilvy Public Relations for Low Battery Anxiety
SILVER AWARD: Ruder Finn for Polaroid Swing
BRONZE AWARD: PAN Communications for roOomy: Intersecting Technology, Real Estate and Interior Design
BRONZE AWARD: IBM for Defining Cognitive Creativity with IBM Watson

Best Travel, Hospitality & Destinations Campaign

GOLD AWARD: Ogilvy Public Relations for OUE Skyspace Taking Tourism to New Heights: Launching OUE Skyspace LA
SILVER AWARD: Murphy O’Brien Public Relations for Thompson Seattle
BRONZE AWARD: Murphy O’Brien Public Relations for The Peninsula Chicago

Best Use of Broadcast Video – Business/Consumer

GOLD AWARD: Klick Communications for 21st Annual Redondo Beach Lobster Festival
SILVER AWARD: Flashpoint PR for A LEGO Yellow Submarine Comes to Life

Best Use of Personality/Celebrity

GOLD AWARD: RF|Binder for Robin Wright: The Path Towards Global Equality | Insight Dialogues
SILVER AWARD: Sallie Mae and Clyde Group for The Dee-1 Campaign
SILVER AWARD: Current for Brita – Drink Amazing
SILVER AWARD: O’Reilly DePalma for Howie Mandel Leads the ActiClean Patrol to Launch a New Self-Cleaning Toilet
SILVER AWARD: Ogilvy Public Relations for LG TONE-Up Your Music
BRONZE AWARD: Hager Sharp for Shaquille O’Neal: Don’t Get Caught Up in the Madness, Download the Virtual Bar App
BRONZE AWARD: GOLD PR | Social Media for Fear No Mirror: Coolsculpting and Molly Sims

Best Use of Research – Business/Consumer

GOLD AWARD: CareerBuilder for CareerBuilder Releases New Study on Which Cities are Most Likely and Least Likely to Survive a Zombie Apocalypse
SILVER AWARD: Ogilvy Public Relations for Low Battery Anxiety
BRONZE AWARD: Ogilvy Public Relations for LG TONE-Up Your Music

Best Use of Social Media – Business/Consumer

SILVER AWARD: French/West/Vaughan for Rodeo Right at your Fingertips
BRONZE AWARD: The Vision Council for The Vision Council’s National Sunglasses Day Consumer Outreach Campaign

Best Use of the Internet – Consumer

GOLD AWARD: Rogers & Cowan for Launch of Funimation Films: Shin Godzilla Release
SILVER AWARD: FirstEnergy for FirstEnergy Scam Prevention & Information Website

Best Website – Business/Consumer

SILVER AWARD: French/West/Vaughan for Wrangler Sets Their Sites High
BRONZE AWARD: FirstEnergy for FirstEnergy Scam Prevention & Information Website

PR Innovation of the Year

SILVER AWARD: North 6th Agency for Fluent Political Pulse
BRONZE AWARD: Havas PR North America for Agile PR: Expert Messaging in a Hyper-Connected, Always-On World

About Bulldog Reporter

Bulldog Reporter provides news and insights to public relations and corporate communications professionals with the mission of helping these practitioners achieve superior performance. Bulldog Reporter publishes a daily newsletter, with a summary of relevant news called the Daily ‘Dog, and runs an industry awards program – the Bulldog Awards – to recognize excellence in public relations and communications.

Awards Program & Media Contact
Whitney Zelmer
Awards & Marketing Coordinator
1.866.849.6944
whitney.zelmer@bulldogreporter.com

SOURCE: Bulldog Reporter

ReleaseID: 457968